Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
波士顿，2024年12月3日（环球新闻通讯） -- Praxis Precision Medicines（纳斯达克：PRAX），一家临床阶段的生物制药公司，正在将基因洞察转化为针对中枢神经系统（CNS）疾病的治疗开发，这类疾病的特征是神经元兴奋-抑制失衡，今天宣布将在2024年12月参加两场即将举办的投资者会议。
- Praxis management will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference, taking place in New York, NY at the Lotte New York Palace Hotel on December 4, 2024 at 2:00pm ET. A live webcast of the event will be available through this link.
- Praxis management will also be participating in a panel titled "Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts" at the Oppenheimer Movers in Rare Disease Summit, taking place in New York, NY at the Westin Grand Central Hotel on December 12, 2024 at 2:00pm ET.
- praxis管理层将参加派杰投资第36届年度医疗保健会议的炉边聊天，该会议将于2024年12月4日下午2:00在纽约市的纽约乐天酒店举行。该活动的现场直播将通过此链接提供。
- praxis管理层还将参加在2024年12月12日下午2:00于纽约市的西雅图万豪酒店举行的"来自罕见疾病公司的电梯推介，具有关键的短期潜在股市推动催化剂"专题小组讨论。
The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective Piper Sandler and/or Oppenheimer representatives to request meetings.
公司将在这些会议期间提供一对一的会议。感兴趣的投资者应联系各自的派杰投资和/或奥本海默代表以请求会议。
The Piper Sandler live webcast will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website at . Following the event, a replay will be posted, when available, to Praxis' website on the "Events and Presentations" page under the investor section of the website for 90 days.
派杰投资的直播网络研讨会也将在公司网站投资者和媒体部分的“即将到来和最近的活动”页面上提供。活动结束后，回放将在可用时发布到praxis precision medicines的网站的“活动和演示”页面，保留90天。
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum, and antisense oligonucleotide (ASO) platform, Solidus, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, LinkedIn and Twitter/X.
关于praxis precision medicines
praxis precision medicines是一家临床阶段的生物制药公司，将从基因癫痫中获得的见解转化为针对中枢神经系统疾病的治疗，这些疾病以神经兴奋与抑制失衡为特征。Praxis正在利用基因见解，通过我们专有的小分子平台Cerebrum和反义寡核苷酸(ASO)平台Solidus，发现和开发针对稀有以及更普遍的神经系统疾病的治疗，利用我们对大脑中共享生物靶标和电路的理解。Praxis已经建立了一个多样化的多模式中枢神经系统产品组合，包括多个运动障碍和癫痫的项目，共有四个临床阶段的候选产品。有关更多信息，请访问并关注我们的Facebook、LinkedIn和Twitter/X。
CONTACT: Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576
联系方式：投资者联系：
praxis precision medicines
investors@praxismedicines.com
857-702-9452
媒体联系：
丹·费里，电话：(617) 430-7576
生命科学顾问
Daniel@lifesciadvisors.com
617-430-7576
